PURPOSE: The aim of this study was to perform structural characterization of a recombinant monoclonal antibody (MAb), huN901, by electrospray time-of-flight mass spectrometry (ESI-TOFMS) using both "top-down" and "bottom-up" approaches. METHODS: In the top-down approach, the molecular masses of the deglycosylated huN901 and the light and heavy chains of the antibody were measured by direct infusion MS and liquid chromatography-mass spectrometry (LC-MS). In the bottom-up approach, trypsin and Asp-N protease were used to digest the separated, reduced and alkylated light and heavy chains followed by LC-MS analysis of the digests. RESULTS: The primary structure and post-translational modifications of huN901 were characterized by both top-down and bottom-up MS approaches. Modifications of N-terminal pyroglutamate formation, cleavage of C-terminal lysine, glycosylation, and deamidation were identified in the antibody heavy chain by both protein mass measurement and peptide mapping. No modifications were found in the complementarity determining regions (CDRs) of both chains. Both trypsin and Asp-N protease digestion had an average sequence recovery of 97%, and generated complimentary mapping results with complete sequence recovery. CONCLUSIONS: ESI-TOFMS is a superior tool to characterize MAb and other complex protein pharmaceuticals.
PURPOSE: The aim of this study was to perform structural characterization of a recombinant monoclonal antibody (MAb), huN901, by electrospray time-of-flight mass spectrometry (ESI-TOFMS) using both "top-down" and "bottom-up" approaches. METHODS: In the top-down approach, the molecular masses of the deglycosylated huN901 and the light and heavy chains of the antibody were measured by direct infusion MS and liquid chromatography-mass spectrometry (LC-MS). In the bottom-up approach, trypsin and Asp-N protease were used to digest the separated, reduced and alkylated light and heavy chains followed by LC-MS analysis of the digests. RESULTS: The primary structure and post-translational modifications of huN901 were characterized by both top-down and bottom-up MS approaches. Modifications of N-terminal pyroglutamate formation, cleavage of C-terminal lysine, glycosylation, and deamidation were identified in the antibody heavy chain by both protein mass measurement and peptide mapping. No modifications were found in the complementarity determining regions (CDRs) of both chains. Both trypsin and Asp-N protease digestion had an average sequence recovery of 97%, and generated complimentary mapping results with complete sequence recovery. CONCLUSIONS: ESI-TOFMS is a superior tool to characterize MAb and other complex protein pharmaceuticals.
Authors: J Bongers; J J Cummings; M B Ebert; M M Federici; L Gledhill; D Gulati; G M Hilliard; B H Jones; K R Lee; J Mozdzanowski; M Naimoli; S Burman Journal: J Pharm Biomed Anal Date: 2000-01 Impact factor: 3.935
Authors: R J Harris; B Kabakoff; F D Macchi; F J Shen; M Kwong; J D Andya; S J Shire; N Bjork; K Totpal; A B Chen Journal: J Chromatogr B Biomed Sci Appl Date: 2001-03-10
Authors: T J Lynch; J M Lambert; F Coral; J Shefner; P Wen; W A Blattler; A R Collinson; P D Ariniello; G Braman; S Cook; D Esseltine; A Elias; A Skarin; J Ritz Journal: J Clin Oncol Date: 1997-02 Impact factor: 44.544
Authors: Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama Journal: Pharm Res Date: 2010-02-09 Impact factor: 4.200
Authors: Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu Journal: MAbs Date: 2018-12-17 Impact factor: 5.857
Authors: Apurva S More; Ronald T Toth; Solomon Z Okbazghi; C Russell Middaugh; Sangeeta B Joshi; Thomas J Tolbert; David B Volkin; David D Weis Journal: J Pharm Sci Date: 2018-05-08 Impact factor: 3.534